MICROENCAPSULATION PROCESS AND PRODUCT

Abstract: This invention relates to the microencapsulation of various materials, in particular pesticidal materials, to produce both wet and dry formulations. In particular, the invention relates to encapsulating such materials by incorporating a PVA into an interfacial polycondensation system for producing microcapsules, and subsequently spray drying the resulting microcapsules in the presence of the PVA, and optionally a further quantity of PVA which may be the same or different from the one adopted in the microencapsulation step, so that the encapsulated product can be diluted in water, in order to produce aqueous pesticidal compositions, which can be applied by conventional spray techniques.

Description: MICROENCAPSULATION PROCESS AND PRODUCT This invention relates to the microencapsulation of various materials, m particular pesticidal materials, to produce both wet and dry formulations. In particular, the invention relates to encapsulating such materials so that the encapsulated product can be diluted in water, m order to produce aqueous pesticidal compositions, wnich can be applied by conventional spray tecnmques . The encapsulation of pesticides, plant growtn regulators, and tr.e lικe s a field wnich has attracted increasing interest m recent years . For safety and ease of distribution, t s particularly convenient to supply sucn materials m tne form of aqueous dispersions of dry solids, which can De dispersed easily m water for field application. Various proposals have been made m recent years for the microencapsulation of various pesticidal materials. For example, US-A-5160530 (Griffm. discloses a process for encapsulating pesticides (for example trifluralm; , by melting the active material, and combining the melted material with a film- orming polymer, such as a polyvmylalcohol (PVA) . The materials are then emuisifiec. together and spray dried. US-A-4244836 (Hoechst) discloses a similar method of encapsulating pesticidal materials, by spray drying a dispersion of the active material and a PVA. Although for some systems, the processes disclosed by these references are useful, they suffer from a number of disadvantages, for example that the active material can diffuse within the product leading to crystallisation of the active material in the PVA matrix, and also articularly m the Griffin method) that undesired pciymorphs of the molten active material may be produced upon cooling to ambient temperature. US-A-4936901 (Monsanto) discloses an alternative method of encapsulation, m which microcapsules contammσ the active material are formed by means of an interfacial polycondensation reaction, involving an lsocyanate/polyamme reaction. The resulting mterfacially polymerised microcapsules are subsequently spray dried. This reference mentions that PVA may be used as a suspension adjuvant n tne spray drying step. Again, this me hoc results in tne production of microcapsules with uncontrollable release characteristics. Also, some active materials show a tendency to diffuse out of the mter acially polymerised microcapsules during storage, thus producing crystallisation (in the case of actives normally solid at ambient temperatures) . Another difficulty with this method is that the products which result all have slow release characteristics, because of their large particle size distribution and thιcκ polymer wall. One particular proolem wnicn this reference does not address at all is the production of microcapsules which provide rapid release of the active material, rather than sustained or delayed release. Often a controlled release formulation will be required to produce a rapid biological effect ("knock-down") followed by a sustained release ("residuality") of the active. Rapid release capsules are generally required to be small m size (typically with a volume mean diameter (VMD) less than 5 micrometres) or have extremely thin polymer shell walls. None of the systems prepared in US-A-4936901 have the small particle size normally required to provide rapid knock-down. The only information about particle size given in the reference is that particle the size distribution (not the VMD) is from 1-50 microns. The surfactants taught as essential to the reference are of a kind which would not be suitable for the formation of such capsules with a VMD of less than 5 micrometres . It s known furthermore from, for example EP-A-0611253 , US-A-5332584 and US-A-5324584 to use PVAs as surfactants or protective colloids m pesticide encapsulation processes. These references do not suggest however that the PVA takes an active part m shell wall formation, such that it can influence and permit effective control over the release characteristics of the microcapsules produced. We have found by incorporating a PVA into an interfacial polycondensation system for producing microcapsules, and subsequently spray drying the resulting microcapsules in the presence of the PVA and optionally a further quantity of PVA which may be the same or different from the one adopted m the microencapsulation step, microcapsules can be obtained which show improved storage stability, especially to the leaching of the active material from the resulting microcapsules, particularly when the microcapsules are small in size, (for example less than 5 micrometer) . Accordingly, in a first embodiment of the invention, there is provided a process for preparing an encapsulated material, which process comprises forming microcapsules containing the material by an interfacial polycondensation reaction, and spray drying the resulting microcapsules in the presence of a polyvinylalcohol (PVA) , wherein the PVA is present during the interfacial polycondensation reaction forming the microcapsules. As indicated above, a further quantity of PVA, which may preferably oe one which is different from the one used in the interfacial polycondensation step, may be added to the mixture containing the microcapsules, prior to the spray drying step. The PVA employed m tne microencapsulation step may be one with a degree of polymerisation of from 50 to 5,000, and a degree of hydrolysis cf from ^0% to 100%. Desirable characteristics for the PVA are that it should be an efficient emulsif er prior to the polycondensation step, that t can assist the stabilisation of the capsules wnilst tney are forming, and also that t can assist tne re- wetting cf tne capsules after spay drying when they are ultimately used. These requirements are not all optimally met m a single PVA grade. A good compromise has been found to be a material having a degree of polymerisation of about 300, and a degree of hydrolysis of about 88%. The additional PVA whicn may be added prior to the spray drying step s mainly selected on the basis of its poor solvent qualities for tne encapsulated material, and for its ease cf re-wettmg m cold (and possibly hard) water. Chemically modified PVAs, suc.i as the sulphonated or carooxylated PVAs, are particularly useful for this purpose . The interfacial polycondensation to form the microcapsules may be carried out by any of the various methods known to those skilled in the art. In a preferred embodiment, the interfacial polycondensation reaction in the presence of the PVA is carried out using a polyisocyanate and a polyamine. Because the PVA is present during the polycondensation reaction which forms the microcapsule walls, and because its surfactant nature ensures both a high concentration and preferred orientation at the oil/water interface, the PVA, having pendant -OH groups, reacts with the isocyanate to incorporate polyurethane groups into the polymeric microcapsule walls. The permeability of polyurethane polymers is quite different from that the of the polyurea which is formed by reaction of the polyisocyanate with the polyamine. Other interfacial polycondensation reactions which may be employed are, for example isocyanate/polyol , isocyanate/water, and isocyanate/acid chloride reactions. The material which is encapsulated mav be a oesticidal material, for example amitraz pnosa one azinphos-ethyl phosfolan azinphos-methyl phosmet benzoximate promecarb bifenthrin quinalphos binapacryl resmethrin bioresmethrin temephos chlorpyrifos tetramethrin chlorpyrifos-methyl xylylcarb cyanophos acrinathrin cyfiuthrin allethrin cypermethrin benfuracarb bromophos bioallethrin bromopropylate bioallethrin S butacarboxim bioresmethrin butoxycarboxin buprofezin chlordimeform chlorfenvinphos chlorobenzilate chlorflurazuron chloropropylate chlormephos chlorophoxim cycloprothrin fenamiphos betacyfluthrin fenobucarb cyhalothrin gamma-HCH cambda-cyhalothrin methidathion alpha-cypermethrin deltamethrin beta-cypermethrin dicofol cyphenothrin dioxabenzafos demeton-S-methyl dioxacarb dichlorvos endosulfan disulfoton EPNethiofencarb edifenphos dinobuton empenthrin tetradifon esfenvalerate tralomethrin ethoprophoε N-2, 3-dihydro-3-methyl-l,3 etofenprox thiazol-2-ylidene-2,4- etrimphos xylidene fenazaquin oarathion methvl fenitrothion fenthiocarb phenothπn fenpropathπn phenthoate fenthion piπmiphos-ethyl fenvalerate piri iphos-methyl flucythrmate profenofos flufenoxuron propaphos tau- f luvalmate propargite f ormothion prcpetamphospyrachlofos hexaflumuron tefiuthrin hydroprene ter ufos isofenphos tetrachloπnphos isoprocarb traiomethrin isoxathion triazopnos malathion pyrachlofos mephospholan tefiuthrin methoprene ter ufos methoxychlor tetrachlσnnphos mevinphos traiomethrin oermetnπn triazoonos the followmσ funσicides benalaxyl biteranol bupiπmate cyproconazole carboxm tetraconazole dodemorph dif noconazole dodine dimethomorph fenaπmol dimconazole ditalimfos ethoxygum myclobutanil etπdiazole nuarimol fenpropid oxycarboxin fluchloralm penconazole flusilazole prochloraz imibenconazole tolclofos-methyl myclobutanil triadimefon propiconazole triadimenol pyπfenox azaconazole tebuconazole epoxyconazole tridemorph fenpropimorph triflumizole the following herbicides:- 2,4-D esters bifenox 2,4-DB esters bromoxynil esters acetochlor bromoxynil aclonifen butachlor alachlor butamifos anilophos butralin benfluralin butylate benfuresate carbetamide bensulide chlornitrofen benzoylprop- thyl chiorpropham cinmethylin flurochloralin haloxyfop clethodim ethoxyethyl clomazone haloxyfop-methyl clopyralid esters ioxynil esters CMPP esters isopropalin cycloate MCPA esters cycloxydim mecoprop-P esters desmedipham metolachlor dichlorprop esters monalide diclofop-methyldiethatyl napropamide dimethachlor nitrofen dinitramine oxadiazon ethalfluralin oxyfiuorfen ethofumesate pendimethalin fenobucarb phenisopham fenoxaprop ethyl phenmedipham fluazifop picloram esters fluazifop-P pretilachlor fluchloralin profluralin fiufencxim propachior fiumetraiin propanil flumetralin propaquizafop fluorodifen pyridate fluoroglycofen ethyl quizalofop-P fluoroxypyr esters triclopyr esters flurecol butyl tridiphane trifluralin Other pesticides such as the nitrification inhibitor nitrapyrin may also be employed. The compositions of the invention may also incorporate mixtures of two or more pesticides which may in some embodiments form a eutectic mixture having a melting point lower than that cf the separate components . The pesticide may be an organosoluble derivative of a pesticidal compound which is itself poorly organosoluble or insoluble. The active material may be present in amounts of, for example, from 30 to 90 weight percent, preferably from 60 to 85 more preferably from 75 to 80 weight percent based on the spray dried formulation. As indicated above, the method of the invention is particularly advantageous for the production of microcapsules having a small particle size, for example having a VMD of 5 micrometer or less, particularly 2 micrometer or less. The chief advantages of such small capsules are that they provide a higher surface area to mass ratio than larger particles, and thus give an ennance release rate and better knock-down. Further, such small capsules can penetrate soil or surface grass thatch better than larger capsules, and so are more efficacious in certain applications where sucn so l or thatch mobility is needed. Yet another benefit of sucn small capsules is that, as the VMD decreases, it is possible to retain greatly increased amounts cf supercooled active m the liquid form. It s tnus possible to produce a reliable manner liquid core capsules witnout tne use of solvents, wnich m turn gives environmental advantages, as well as higner active loadings m the final product. The presence of a liquid core in capsules made with a supercooled molten active has several advantages, of which the most significant from point of view of the present invention is that a liquid core will general release it active more rapidly than will a solid. This combined with small particle size gives a significant increase m active release rate. A second advantage is that the core does no crystallise, thus causing rupture of the capsules, which can lead both to premature release, and to formulation instability on storage. A third advantage of retaining th active m the liquid state is that there is no possibility of producing a biologically less active polymorph during crystallisation - a problem which is addressed in another way in US-A-5160530 (Griffin) . Clearly, where the active is dissolved in a solvent, these problems are not encountered. Any water-insoluble solvent may be employed if a solvent is deemed desirable. Examples of typical solvents are aromatic solvents, particularly alkyl substituted benzenes such as xylene or propyl benzene fractions, and mixed naphthalene and alkyl naphthalene fractions; mineral oils; kerosene, dialkyl amides of fatty acids, particularly the dimethyl amides of fatty acids such as the dimethyl amide of caprylic acid; chlorinated aliphatic and aromatic hydrocarbons such as 1, 1, 1-trichloroethane and chiorobenzene, esters of glycol derivatives, such as the acetate cf the n-butyl, ethyl, or methyl ether of diethyleneglvcol, the acetate of the methyl ether of dipropyleneglycoi, ketones such as isophorone and trimethylcyclohexanone (dihydroisophorone) and the acetate products such as hexyi, or heptylacetate . The preferred organic liquids are xylene, propyl benzene fractions, alkyl acetates, and alkyl naphthalene fractions. An advantage of the encapsulation method which the PVA is present during the encapsulation reaction, is that by altering the time before the addition of the polyamine, the amount of polyurethane and pol urea in the capsule wall can be controlled with some accuracy. Since these two polymers have very different diffusivities for the encapsulated material, this ratio cf poiyurethane/polyurea provides a further, independent method for controlling the release rate of the active, addition to the control provided by varying capsule wall thickness and capsule size. In another embodiment, the solvent may be a polymerisable monomer for example an ethylenically unsaturated monomer (such as styrene, alphamethlystyrene, (m) ethylmethacrylate, a vinyly halide, or acrylonitrile) which is subsequently polymerised to give a matrix core to the capsules, thus adding further to the control of the release rate of the active. A further advantage of the encapsulation method wnich the PVA is present during the encapsulation reaction, is that because of its multiplicity of pendant -OH groups, tne PVA becomes chemically bonded to the capsule wall during the shell-forming reaction. This bonding produces some terminally attached PVA ("tails") , some doubly attached PVA ("loops") and some multiply attached PVA '"trains") . Having non-attached PVA present particularly during the subsequent spray drying step to produce a dry product may be a disadvantage. In spray drying, the concentration (of PVA, capsules and any added solutes, for example, salts) rises very rapidly. The intention is to produce a uniform layer of water-soluble polymer around eacn capsule, and that tms should film-form wnen dry It s clear that depletion flocculaticn may occur as tne concentration increases during the drying process. Thus capsule-capsule contacts may occur, leading to irreversible coagulation. The presence cf loops and trains affords a substantial measure of protection against both these causes of poor re-wetting and colloidal instability. They also have a further significant benefit, that they allow suϋstantial amounts of electrolyte to be added to the capsule suspension, and such electrolytes assist the QUICK re-wett g of tne dried product, as taugnt EP-A2- 0563379 (Rohm & Haas) . The addition cf any high concentration of electrolyte to conventional capsule suspensions generally leads to irreversible coagulation of the capsules. A further advantage of the encapsulation method in accordance with the invention is that it permits the production of dry compositions containing two or more active materials, where the materials are such that direct formulation of the materials (ie, without encapsulation of one or both of them) would lead to a product which is chemically or physically unstable. In one aspect, the sai actives may be separately encapsulated, but an alternative and preferred embodiment, one or more of the active materials (or some portion of a single active material) may be encapsulated by the metnod accordance with the invention, and the balance not encapsulated. In this way, the unencapsulated active material is immediately biologically available upon application, whereas the encapsulated material is released more slowly. The amount of each material employed sucn different forms will vary dependent upon the particular application but m general terms, each such material may constitute from 0.1 to 99.9% oy weight of tne total cf tne encapsulated material. The microcapsules accordance with the invention may be prepared by nign shear mixing of a solution or a melt containing the active material (eg. pesticide) the PVA (as an aqueous solution 1 , and one of tne materials for producing the interfacial polycondensation (eg. isocyanate) . The PVA acts as an emulsifier, and m some systems, no furtner emulsifier may be required. It is desirable however to add additional emuisifiers, which may be of generally known type order to produce tne desired emulsion of small particle size. When the size of the emulsion is as desired, tnen the other polymeric cross- linker is added (eg. polyamine) , to complete the interfacial polycondensation. As indicated above, a preferred reactant for the polycondensation is a polyamine, which is usually a water soluble, reactive polyamine, such as diethylene triamine or tetraethylene pentamine. These amines start to react with the isocyanate at the interface as soon as they are added to the emulsion. More complete control can sometimes be achieved by using either a water-soluble amine salt, or an oil-soluble amine salt, dissolved respectively in the aqueous phase or the oil phase at an- early stage in the process (for example, before emuisif cation) . By virtue cf the fact that they are salts, they do not immediately reac t with the isocyanate, out do so promptly when the pH is adjusted to liberate the free amine, whereupon cross- linking occurs . The high shear mixing can be performed on a batch of the ingredients, or may be conducted continuously (in¬ line, 1 . In the former case, the time of addition or release of tne reactive amine is governed by the processing time required to form the emulsion wit the correct particle size distribution 'whicn clearly s paten size dependent^ , wniist m tne latter case, tne interfacial reaction can oe petter controlled, since tne amme can be added/released at any desired time simply by choice cf injection point the process stream, thus giving essentially complete control over tne urea/urethane ratio. As indicated above, all of tne PVA employed m the process cf the invention may be added at the outset, for formation cf the microcapsules. Usually, however, it is preferable to add additional PVA after microcapsule formation, but before spray drying. The ratio of the amount of PVA added at the second stage to that added initially present is typically at least 0.5:1. Other conventional additives may also be incorporated into the formulation such as emulsifiers, dispersants, disintegration aids, salts and film-forming polymers. A number of preferred embodiments of the invention are described in the following Examples, and certain characteristics of those Examples are illustrated in the accompanying drawings, which: - 13 ' Figure 1 illustrates tne dependence of crystaliinity on VMD, and Figure 2 illustrates the effect of crystaliinity on residuality. Example 1 An emulsion was prepared by high shear mixing of an aqueous 20% w/w PVA solution (GL03, Nippon Gohsei, 88% hydroiysed, degree of polymerisation approximately 300) maintained at 55°C a water bath. Molten chlorpyrifos was mixed witn a polymeric isocyanate (VORANATΞ M220j tne amount shown oelow, and tne mixture added to the PVA solution in the water bath, under hiσh shear. Chiorpyrifos technical 93.9g Voranate M220 4.7g GL03 12g as 15% w/w solution Diethylene tnamme 1.25g dissolved 65g water In samples of around lOOg or so, a mixing t me of 30 seconds was sufficient to reduce the VMD to below one micrometer, whilst for larger samples (500g) a time of around 90 seconds was needed to reach a VMD of around o: micrometer. When the target VMD was achieved, the diethylene- triamine was added under hiσh shear. Reaction of the isocyanate with the polyamine and PVA produced microcapsules containing the active material dispersed in the aqueous phase. To produce a dry product, the wet capsule phase was then mixed (5kg) with 0.855kg GL03 as a 21% aqueous solution together with deionised water to adjust the suspension viscosity to an appropriate level for spray drying (conveniently about 100 mPas.. The icrocapsule suspension was spray-dried producing a dry product 5 containing approximately 75% w/w cnlorpyπfos . The further PVA was such as to provide a ratio of approximately 66 percent of the first PVA, and 33 percent of tne furtner PVA the dry product. The spray drying was carried out using an inlet temperature of from 120°C to 150°C, and an outlet C temperature of from 65°C to 85°C. The product was a slightly off white free flowing powder with a water content of approximately 3.5 percent. The particle size (vmd) of tne wet capsule product and cf the cry product wnen put nto water and allowed to disperse were botn about 1 5 micrometre. Release rate test The release rate of the product was tested by spraying 0 a dilution containing 1000 ppm by weignt of active material onto glass slides and measuring the amount left after storing the slides m a fixed temperature environment at 20°C with constant air-flow for 24 hours. The product from Example 1 gave a residual figure cf 95% retained on the 5 glass slide. Example 2 Wet capsules were prepared in a similar manner to 0 Example 1, but as a continuous process using an "in-line" mixer, and using the following recipe :- Chlorpyrifos technical 93.9g Voranate M220 2.94g 5 GL03 16.8g as a 21% aqueous solution Diethylenetriamme 1.56g dissolved 65g water This wet capsule phase (5kg) was then mixed with 200g of a 10% solution of a carboxylated PVA (Trade Mark KM118) and spray-dried as described above to produce a dry product containing approximately 75% w/w chlorpyrifos . The particle size (VMD) cf the wet capsule product and the dry product when put into water and allowed to disperse was about 0.6 micron. A glass slide residue test with this product showed only 30% remaining after a 24 hour storage period, illustrating the control over the release characteristics possible with this invention. The chief differences between Examples 1 and 2 are: (i) Example 1 has more isocyanate, and therefore thicker walls than Example 2. (ii) Example- 1 has a larger VMD than Example 2, and so has a proportionately lower interfacial area. (iii) Because Example 2 was made in-line, and Example I was made by a batch process, the amine was added earlier in Exampl ' e 2 than in Example 1. (iv) Because of its increased particle size (VMD = 1 μm) , Example 1 was more crystalline than Example 2, with about 10% in the solid form, compared to a VMD cf about 0.55 μm and % crystalline of about 3% for Example 2. Each of these factors results in a more rapid release for Example 2 than for Example 1, as is clearly shown by the very much lower amount of active retained at 24h for Example 2 than for Example 1. The excellent correlation between % crystallised and the % retained at 24h on a glass slide is shown by Figure 2. Examples 2 to 6 Further compositions were prepared by the same genera method as in Example 1, by varying the amounts of the materials as shown in Table 1 (amounts are in grams) . Table 1 illustrates the ease with which release characteristics may be controlled. TABLE 1 All these wet capsule systems were mixed with GL03 in sufficient quantity to produce a 75% chlorpyrifos product and spray-dried according to the technique outlined above. In a comparative study employing a methyl-capped nonionic surfactant (ATLOX 4849B) used as a direct replacement for the PVA in Example 6 above a particle size of 0.45 microns was achieved. This product was then sprayed dried, but unsuccessfully, forming a waxy deposit in the spray-drier. All the products of the invention Examples 1-6 were spray-dried high yield and were stable on storage. Examples 7 to 9 Three products were prepared from the following recipe : Chlorpyπfos tecnnical 95.06g Voranate M220 2.94g GL03 7.54g Water 30.16σ All these emulsified to produce an emuisicn at 50 deg C to which was then added: Diethyienetπamine 1.90g in 77.7g water * In each of these Examples the time taken before addition of diethylenetriamine was varied so as to alter the ratio cf polyurea and polyurethane in the capsule wall This was measured by an infra-red technique. The Release rates on these three different batches were measured as before. Table 2 It can be seen that altering the urea:urethane ratio with this technique is a useful tool with which to control the release characteristics of a product. In a similar manner a series of products was prepared whereby the release rate was varied from about 100% remaining after 24 hours to less than 10% just by alteration of the urea :urethane ratio by the techniσue described above. Example 10 Chlorpyrifos-methyl was dissolved an aromatic solvent (Solvesso 200) and then encapsulated using the tecnn σue above, using tne following recipe. Chlorpyrifos-methyl 42g (technical) Solvesso 200 20g Voranate M-229 ig GL03 , 4g (as a 10% aqueous solution) diethyienetriamme 0.3g dissolved 9.7g water. This wet capsule phase had a particle size (v d) of 1.72 microns. The product was mixed with sufficient PVA solution (GL03) to produce a dry product containing approximately 50% w/w chlorpyrifos-methyl when spray dried as above to give a free-flowing powder containing about 50% w/w chlorpyrifos-methyl as an encapsulated product. This product was stable on storage, releasing the small capsules readily on addition to water. The product on addition to water produced a particle size (vmd) of 1.66 microns, demonstrating the ability of such products to disperse back to the wet capsule size distribution on addition to water. Example 11 A series of products containing chlorpyrifos were prepared with different particle size distributions and these products were stored at ambient temperature . Chlorpyrifos has a melting point of about 40-42 deg C. At ambient temperature, such encapsulated products would be expected to crystallise over a period of time. The occurrence of crystallisation can be determined by the use of Differential Scanning Calorimetry (DSC) where the melting-point endotherm can be used to indicate how much of a product is in the crystalline state. Using this technique it was found that surprisingly very little chlorpyrifos crystallised in the systems of the invention, as compared to a product prepared according to US-A-516053C (Griffin) in which chlorpyrifos was emulsified in a solution of PVA and then spray-dried to produce a dry product . Figure 1 illustrates the dependence of the measured crystaliinity on particle VMD, for a number of compositions in accordance with the invention, as compared with the corresponding Example produced according to US-A-5160530 ("Griffin Example") . It can be seen that the Griffin Example has a degree of crystaliinity of about 30%, with a VMD of 0.4 micrometres, whilst the expected value for a material of this size encapsulated in accordance with the invention would be about 3%. Clearly the encapsulation results in a surprising stabilisation of the metastable liquid state. The effect of crystaliinity (and thus, indirectly, of particle size) on residuality is illustrated in Figure 2. Very little crystallisation is seen with products of the invention (up to 15% with a 2.2 micron (vmd) capsule) but about 30% with a product of the Griffin route (which actually had a vmd for the emulsion of about 0.4 micrometer) .

Claims: Claims 1. A process for preparing an encapsulated material, whicn process comprises forming microcapsules containing the material by an interfacial polycondensation reaction, and spray drying the resulting microcapsules in the presence of a polvvinylaicohol (PVA) , characterised in that the PVA is present during the interfacial polycondensation reaction forming the microcapsules . 2. A process as claimed in Claim 1, wherein a further quantity of a PVA is added to the mixture containing the said microcapsules, prior to the said spray drying step. 3. A process as claimed m Claim 2, wherein the said further quantity of PVA added prior to the said spray drying step is a different PVA from the one employed during the interfacial polycondensation. 4. A process as claimed m any one of the preceding claims, wherein the first PVA has a degree of hydrolysis of from 70 to 100%, and a degree of polymerisation of "at least 50. 5. A process as claimed m Claim 4, wherein the first PVA has a degree of hydrolysis of about 88%, and a degree of polymerisation of about 300. 6. A process as claimed in any one of the preceding claims, wherein the second PVA is a carboxylated or sulphonated PVA. 7. A process as claimed in any one of the preceding Claims, wherein the microcapsules are formed by the reaction of a polyisocyanate with a polyamine. 8. A process as claimed in any one of the preceding Claims, wherein the encapsulated material is present in an amount of from 30 to 95 weight percent of the spray dried microcapsules . . A process as claimed in Claim 8 wherein the encapsulated product is present in an amount of from 60 to 85 weight per cent of the spray dried microcapsules. 10. A process as claimed in Claim 9 wherein the encapsulated product is present in an amount of from 75 tc 30 weight per cent of the spray dried microcapsules. 11. A process as claimed in any one of the preceding Claims, wherein the spray dried microcapsules have a volume median particle size of 5 micrometer or less. 12. A process as claimed in Claim 11, wherein the spray dried microcapsules have a volume median particle size of 2 micrometer or less. 13. A process as claimed in any one of the preceding Claims, wherein the material to be encapsulated is present in the form of a solution in a solvent. 14. A process as claimed in any one of the preceding Claims, wherein the said material is a pesticidal material. 15. Microcapsules formed by a encapsulating an active material by an interfacial polycondensation reaction, and spray drying the resulting product in the presence of a polvvinylaicohol (PVA) , characterised in that the PVA is present during the interfacial polycondensation reaction forming the microcapsules. 16. Microcapsules as ciaimed in claim 15, wherein the encapsulated material is present in the microcapsules in a liquid state. 17. Microcapsules as claimed in Claims 15 or Claim 16, which contain at least two different pesticides. IS. Microcapsules as ciaimed in Claim 17 wherein the said at least two different pesticides are seperately encapsulated. 19. Microcapsules as claimed in Claim 17 or Claim IS, comprising both relatively slow- and relatively fast- reieas g microcapsules. capsules .

Inventors: LUBETKINS STEVEN DUFF, MULQUEEN PATRICK JOSPEH, SMITH GEOFF, LUBETKINS, STEVEN, DUFF, MULQUEEN, PATRICK, JOSPEH, SMITH, GEOFF
Applicants: DOWELANCO, LUBETKINS STEVEN DUFF, MULQUEEN PATRICK JOSPEH, SMITH GEOFF, LUBETKINS, STEVEN, DUFF, MULQUEEN, PATRICK, JOSPEH, SMITH, GEOFF
Application year: 1995
Main classification: B01J13
IPC codes: A01N25, B01J13